Q-omics provides the consensus-scored ZFP37 profile across patient tissues and cancer cell-line models. ZFP37 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZFP37 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, ZFP37 RNA expression shows 19,960 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where ZFP37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFP37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFP37 survival associations across molecular data types. ZFP37 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFP37 RNA expression–survival associations across cancer types. High ZFP37 expression shows unfavorable associations in ACC and ESCA, but favorable associations in KIRC, SKCM, UCS and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZFP37 RNA expression.
This table summarizes ZFP37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZFP37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFP37 shows lower tumor expression in KICH, BRCA, KIRC and UCEC and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher ZFP37 RNA expression in tumor versus normal tissue (log2 FC = +0.476, t-test p < 0.001).
This table shows molecular features associated with ZFP37 in patient tissues and cancer cell lines. In patient samples, ZFP37 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFP37 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
